Keeping Your Patient with Heart Failure Safe: A Review of Potentially Dangerous Medications

Archives of Internal Medicine

Volumn 164, Issue 7, 2004, Pages 709-720

  Amabile, Celene M ^a,b   Spencer, Anne P ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b Maricopa Integrated Health System   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACETYLSALICYLIC ACID; AMPHETAMINE DERIVATIVE; ANAGRELIDE; ANTIARRHYTHMIC AGENT; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTIINFLAMMATORY AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARBAMAZEPINE; CELECOXIB; CILOSTAZOL; CLOZAPINE; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; DOXAZOSIN; ERGOT ALKALOID; HEMATOLOGIC AGENT; HERBACEOUS AGENT; IBUTILIDE; ITRACONAZOLE; METFORMIN; NONSTEROID ANTIINFLAMMATORY AGENT; PERGOLIDE; PRAZOSIN; ROFECOXIB; SOTALOL; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG;

ANGINA PECTORIS; AORTA VALVE REGURGITATION; ASPERGILLOSIS; ASTHMA; ATRIOVENTRICULAR BLOCK; ATTENTION DEFICIT DISORDER; CARDIOMYOPATHY; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; COMPLEX PARTIAL SEIZURE; DEPRESSION; DIABETES MELLITUS; DISEASE EXACERBATION; DRUG ANTAGONISM; DRUG CHOICE; DRUG CONTRAINDICATION; DRUG FATALITY; DYSPEPSIA; DYSPNEA; EDEMA; FLUID RETENTION; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE REVASCULARIZATION; HEART PALPITATION; HEART PROARRHYTHMIA; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE TACHYCARDIA; HISTOPLASMOSIS; HOSPITALIZATION; HUMAN; HYPERTENSION; HYPOKALEMIA; INSOMNIA; LACTIC ACIDOSIS; LIVER TOXICITY; LUNG EDEMA; META ANALYSIS; MOOD DISORDER; MORBIDITY; MORTALITY; MUSCLE WEAKNESS; NARCOLEPSY; NEUROPATHIC PAIN; ONYCHOMYCOSIS; ORTHOSTATIC HYPOTENSION; PACKAGING; PARKINSON DISEASE; PATIENT CARE; PERIPHERAL EDEMA; PERIPHERAL VASCULAR DISEASE; PHARMACEUTICAL CARE; PLEURAL FIBROSIS; POLYCYTHEMIA; POLYDIPSIA; POLYURIA; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; RESTLESS LEGS SYNDROME; RETROPERITONEAL FIBROSIS; REVIEW; RISK BENEFIT ANALYSIS; RISK FACTOR; SCHIZOPHRENIA; SIDE EFFECT; SINUS BRADYCARDIA; SODIUM RETENTION; SUDDEN DEATH; SYSTOLIC HEART MURMUR; TACHYCARDIA; THROMBOCYTOSIS; TREATMENT INDICATION; UPPER RESPIRATORY TRACT INFECTION; VALVULAR HEART DISEASE; VASCULAR HEADACHE; WEIGHT GAIN;

ADVERSE DRUG REACTION REPORTING SYSTEMS; ANTI-INFLAMMATORY AGENTS; CARDIOVASCULAR AGENTS; CENTRAL NERVOUS SYSTEM AGENTS; DRUG INTERACTIONS; DRUG THERAPY; HEART FAILURE, CONGESTIVE; HUMANS; HYPOGLYCEMIC AGENTS; POLYPHARMACY; RISK FACTORS;

EID: 1842681517     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.164.7.709     Document Type: Review

References (92)

1. O'Connell J, Bristow M. Economic impact of heart failure in the United States: time for a different approach. J Heart Lung Transplant. 1994;13(suppl): S107-S112.
2. Kannel W. Epidemiology and prevention of cardiac failure: Framingham Study insights. Eur Heart J. 1987;8(suppl F):23-26.
3. Dukes MNG, Aronson JK, eds. Meyler's Side Effects of Drugs. Amsterdam, the Netherlands: Elsevier Science BV; 2000.
4. Kearney MT, Wright DJ, Tan LB. Cardiac disorders. In: Davies DM, Ferner RE, de Glanville H, eds. Davies's Textbook of Adverse Drug Reactions. 5th ed. London, England: Chapman & Hall Medical; 1998:119-168.
5. Spilker B. Concept of cause and effect. In: Spilker B, ed. Guide to Clinical Trials. Philadelphia, Pa: Lippincott Williams & Wilkins; 1991:530.
6. Whitworth J. Mechanisms of glucocorticoid-induced hypertension. Kidney Int. 1987;31:1213-1224.
7. Toogood J, Lefcoe N, Haines D. A graded dose assessment of asthma. J Allergy Clin Immunol. 1977;59:298-308.
8. Toogood J, Baskerville J, Jennings B. Influence of dosing frequency and schedule on the response of chronic asthmatics to the aerosol steroid, budesonide. J Allergy Clin Immunol 1982; 70:288-298.
9. Barnes P, Pedersen S. Efficacy and safety of inhaled corticosteroids in asthma: report of a workshop held in Eze, France, October 1992. Am Rev Respir Dis. 1993;148(4, pt 2):S1-S26.
10. Heerdink E, Leufkens H, Herings R, Ottervanger J, Striker B, Bakker A. NSAIDs associated with increased risk of congestive heart failure in elderly patients taking diuretics. Arch Intern Med. 1998; 158:1108-1112.
11. Page J, Henry D. Consumption of NSAIDs and the development of congestive heart failure in elderly patients. Arch Intern Med. 2000;160:777-784.
12. Whelton A, Fort J, Puma J. Cyclooxygenase-2-specific inhibitors and cardiorenal function: a randomized, controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients. Am J Ther. 2001;8:85-95.
13. Nawarskas J SS. Does aspirin interfere with the therapeutic efficacy of angiotensin-converting enzyme inhibitors in hypertension or congestive heart failure? Pharmacotherapy. 1998;18:1041-1052.
14. Singh S, Fletcher R, Fisher S, et al. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. N Engl J Med. 1995;333:77-82.
15. Hunt SA, Baker DW, Chin MH, et al, American College of Cardiology/American Heart Association. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to revise the 1995 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol. 2001;38:2101-2113.
16. Torp-Pedersen C, Moller M, Bloch-Thomsen P, et al. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. N Engl J Med. 1999;341:857-865.
17. Kjekshus J. Arrhythmias and mortality in congestive heart failure. Am J Cardiol. 1990;65:421-481.
18. Kottkamp H, Budde T, Lamp B, Haverkamp W, Borggrefe M, Breithardt G. Clinical significance and management of ventricular arrhythmias in heart failure. Eur Heart J. 1994;15(suppl D):155-163.
19. Echt D, Liebson P, Mitchell L. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. N Engl J Med. 1991;324:781-788.
20. Hallstrom A, Anderson J, Carlson M. Time to arrhythmic, ischemic, and heart failure events: exploratory analyses to elucidate mechanisms of adverse drug effects in the cardiac arrhythmia suppression trial. Am Heart J. 1995;130:71-79.
21. Flaker G, Blackshear J, McBride R, Kronmal R, Halperin J, Hart R. Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation. J Am Coll Cardiol. 1992;20:527-532.
22. Antonaccio M, Gomoll A. Pharmacologic basis of the antiarrhythmic and hemodynamic effects of sotalol. Am J Cardiol. 1993;72:27A-37A.
23. Lehmann M, Hardy S, Archibald D, Quart B, MacNeil D. Sex difference in risk of torsade de pointes with D,L-sotalol. Circulation. 1996;94:2535-2541.
24. Soyka L, Wirtz C, Spangenberg R. Clinical safety profile of sotalol in patients with arrhythmias. Am J Cardiol. 1990;65:74A-81A.
25. Waldo A, Camm A, deRuyter H, et al. Effect of D-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. Lancet. 1996;348:7-12.
26. Hohnloser S, Zabel M, Krause T, Just H. Short- and long-term antiarrhythmic and hemodynamic effects of D,L-sotalol in patients with symptomatic ventricular arrhythmias. Am Heart J. 1992; 123:1220-1224.
27. Ellenbogen K, Stambler B, Wood M, Sager P, Wesley R, Meissner M. Efficacy of intravenous ibutilide for rapid termination of atrial fibrillation and atrial flutter: a dose-response study. J Am Coll Cardiol. 1996;28:130-136.
28. ALLHAT Officers and Coordinators for ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone. JAMA. 2000; 283:1967-1975.
29. Cohn J, Archibald D, Ziesche S, et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure: results of a Veterans Administration Cooperative Study. N Engl J Med. 1986; 314:1547-1552.
30. Packer M, O'Conner C, Ghali J, et al. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. N Engl J Med. 1996;335: 1107-1114.
31. Cohn J, Ziesche S, Smith R, et al. Effect of the calcium antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with enalapril. Circulation. 1997;96: 856-863.
32. Parameshwar J, Poole-Wilson P. The role of calcium antagonists in the treatment of chronic heart failure. Eur Heart J. 1993;14(suppl A):38-44.
33. Elkayam U. Calcium channel blockers in heart failure. Cardiology. 1998;89(suppl 1):38-46.
34. Ferlinz J, Gallo C. Responses of patients in heart failure to long-term verapamil administration [abstract]. Circulation. 1984;70(suppl 2):305.
35. Goldstein R, Boccuzzi S, Cruess D, Nattel S. Diltiazem increases late-onset congestive heart failure in postinfarction patients with early reduction in ejection fraction. Circulation. 1991;83:52-60.
36. Elkayam U, Amin J, Mehra A, Vasquez J, Weber L, Rahimtoola S. A prospective, randomized, double-blind, crossover study to compare the efficacy and safety of chronic nifedipine therapy with that of isosorbide dinitrate and their combination in the treatment of chronic heart failure. Circulation. 1990;82:1954-1961.
37. Minderjahn K, Hanrath P, Bleifeld W. The influence of nisoldipine on rest and exercise hemodynamics of the left ventricle in chronic heart failure insufficency [in German]. Z Kardiol. 1983;72 (suppl 1):83-98.
38. Gheorghiade M, Hall V, Goldberg D, Levine T, Goldstein S. Long-term clinical and neurohormonal effects of nicardipine in patients with severe heart failure on maintenance therapy with angiotensin converting enzyme inhibitors [abstract]. J Am Coll Cardiol. 1991;17(suppl A):274A.
39. Kratz S. Safety of calcium antagonists in patients with congestive heart failure. Clin Ther. 1997;19 (suppl A):92-113.
40. Multicenter Diltiazem Postinfarction Trial Research Group. The effect of diltiazem on mortality and reinfarction after myocardial infarction. N Engl J Med. 1988;319:385-392.
41. McKay C, Chatterjee K, Ports T, Holly A, Parmley W. Minoxidil therapy in chronic congestive heart failure: acute plus long-term hemodynamic and clinical study. Am Heart J. 1982;104:575-580.
42. Nathan M, Rubin S, Siemienczuk D, Swan H. Effects of acute and chronic minoxidil administration on rest and exercise hemodynamics and clinical status in patients with severe, chronic heart failure. Am J Cardiol. 1982;50:960-966.
43. Franciosa J, Jordan R, Wilen M, Leddy C. Minoxidil in patients with chronic left heart failure: contrasting hemodynamic and clinical effects in a controlled trial. Circulation. 1984;70:63-68.
44. Markham R, Gilmore A, Pettinger W, Brater D, Corbett J, Firth B. Central and regional hemodynamic effects and neurohumoral consequences of minoxidil in severe congestive heart failure and comparison to hydralazine and nitroprusside. Am J Cardiol. 1983;52:774-781.
45. Group UKPDS. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352:854-865.
46. Howlett H, Bailey C. A risk-benefit assessment of metformin in type 2 diabetes mellitus. Drug Saf. 1999;20:489-503.
47. Stumvoll M, Nurjhan N, Perriello G. Metabolic effects of metformin in non-insulin dependent diabetes mellitus. N Engl J Med. 1995;333:550-554.
48. Misbin R, Green L, Stadel B, Gueriguian JL, Gubbi A, Fleming GA. Lactic acidosis in patients with diabetes treated with metformin [letter]. N Engl J Med. 1998;338:265.
49. Rosiglitazone (Avandia) [package insert]. Philadelphia, Pa: SmithKline Pharmaceuticals; 2001.
50. Pioglitazone (Actos) [package insert]. Indianapolis, Ind: Eli Lilly Co; 2002.
51. Oertel M. Anagrelide, a selective thrombocytopenic agent. Am J Health Syst Pharm. 1998;55: 1979-1986.
52. Hoffman R. Polycythemia vera. In: Hoffman R, Benz E, Shattil S, eds. Hematology: Basic Principles and Practice. New York, NY: Churchill-Livingstone; 2000:1130-1155.
53. Anagrelide Study Group. Anagrelide, a therapy for thrombocythemic states: experience in 577 patients. Am J Med. 1992;92:69-78.
54. Agrylin (Anagrelide) [package insert]. Eatontown, NJ: Robert Pharmaceutical Corp; 1999.
55. Pietal (Cilostazol) [package insert]. Tokushima, Japan: Pharmacia & Upjohn OPC Ltd; 2002.
56. CNS stimulants: amphetamine monograph. In: Kastrup EK, ed. Drug Facts and Comparisons: Updated Monthly. St Louis, Mo: Facts and Comparisons; 2002: chap 7.
57. Apfelbaum J, Caravati E, Kerns W, Bossart P, Larsen G. Cardiovascular effects of carbamazepine toxicity. Ann Emerg Med. 1995;25:631-635.
58. Labrecque J, Cote M, Vincent P. Carbamazepine-induced atrioventricular block. Am J Psychiatry. 1992;149:572-573.
59. Hewetson K, Ritch A, Watson R. Sick sinus syndrome aggravated by carbamazepine therapy for epilepsy. Postgrad Med J. 1986;62:497-498.
60. Faisy C, Guerot E, Diehl J, Rezgui N, Labrousse J. Carbamazepine-associated severe left ventricular dysfunction. J Toxicol Clin Toxicol. 2000;38: 339-342.
61. Conley R, Optimizing treatment with clozapine. J Clin Psychiatry, 1998;59(suppl 3):44-48.
62. Alvir J, Lieberman J, Safferman A, Schwimmer J, Schaaf J. Clozapine-induced agranulocytosis: incidence and risk factors in the United States. N Engl J Med. 1993;329:162-167.
63. Young CR, Bowers MB Jr, Mazure CM. Management of the adverse effects of clozapine. Schizophr Bull. 1998;24:381-390.
64. Kilian J, Kerr K, Lawrence C, Celermajer D. Myocarditis and cardiomyopathy associated with clozapine. Lancet. 1999;354:1841-1845.
65. Povlsen U, Noring U, Fog R, Gerlach J. Tolerability and therapeutic effect of clozapine: a retrospective investigation of 216 patients treated with clozapine for up to 12 years. Acta Psychiatr Scand. 1985;71:176-185.
66. Leo R, Kreeger J, Kim K. Cardiomyopathy associated with clozapine. Ann Pharmacother. 1996; 30:603-605.
67. Brown S. Excess modality of schizophrenia: a meta-analysis. Br J Psychiatry. 1997;171:502-508.
68. Redfield MM, Nicholson WJ, Edwards WD, Tajik AJ. Valve disease associated with ergot alkaloid use: echocardiographic and pathologic correlations. Ann Intern Med. 1992;117:50-52.
69. Hauck A, Edwards W, Danielson G, Mullany C, Bresnahan D. Mitral and aortic valve disease associated with ergotamine therapy for migraine: report of two cases and review of literature. Arch Pathol Lab Med. 1990;114:62-64.
70. Bana DS, MacNeal PS, LeCompte PM, Shah Y, Graham JR. Cardiac murmurs and endocardial fibrosis associated with methysergide therapy. Am Heart J. 1974;88:640-655.
71. Graham J, Suby H, LeCompte P, Sadowsky N. Fibrotic disorders associated with methysergide therapy for headache. N Engl J Med. 1966;274: 359-368.
72. Shaunak S, Wilkins A, Pilling JB, Dick DJ. Pericardial, retroperitoneal, and pleural fibrosis induced by pergolide. J Neurol Neurosurg Psychiatry. 1999;66:79-81.
73. Pritchett AM, Morrison JF, Edwards WD, Schaff HV, Connolly HM. Valvular heart disease in patients taking pergolide. Mayo Clin Proc. 2002;77: 1280-1286.
74. Dalack G, Roose S, Glassman A. Tricyclics and heart failure. Am J Psychiatry. 1991;148:1601.
75. Howland J, Poe T, Keith J. Cardiomyopathy associated with tricyclic antidepressants. South Med J. 1983;76:1455-1456.
76. Young R, Alexopoulos G, Shamoian C, Dhar A, Kutt H. Heart failure associated with high plasma 10-hydroxynortriptyline levels. Am J Psychiatry. 1984; 141:432-433.
77. Marti V, Ballester M, Obrador D, Udina C, Moya C, Pons-Llado G. Reversal of dilated cardiomyopathy after chronic tricyclic antidepressant drug withdrawal. Int J Cardiol. 1995;48:192-194.
78. Banner A, Sunderrajan E, Agrwal M, Addington W. Arrhythmogenic effects of orally administered bronchodilators. Arch Intern Med. 1979;139:434-437.
79. Mettauer B, Rouleau J, Burgess J. Detrimental arrhythmogenic and sustained beneficial hemodynamic effects of oral salbutamol in patients with chronic congestive heart failure. Am Heart J 1985; 109:840-847.
80. Breeden C, Safirstein B. Albuterol and spacer-induced atrial fibrillation. Chest. 1990;98:762-763.
81. Bouvy M, Heerdink E, Bruin MD, Herings R, Leufkens H, Hoes A. Use of sympathomimetic drugs leads to increased risk of hospitalization for arrhythmias in patients with congestive heart failure. Arch Intern Med. 2000;160:2477-2480.
82. Newnham D, McDevitt D, Lipworth B. The effects of furosemide and triamterene on hypokalemic and electrocardiographic responses to inhaled terbutaline. Br J Clin Pharmacol. 1991;32: 630-632.
83. Goldberger J. Treatment and prevention of sudden cardiac death: effect of recent clinical trials. Arch Intern Med. 1999;159:1281-1287.
84. Eisenberg D, Davis R, Ettner S. Trends in alternative medicine use in the United States, 1990-1997. JAMA. 1998;280:1569-1575.
85. Valli G, Giardina E. Herbal therapies with cardiovascular effects. J Am Coll Cardiol. 2002;39:1083-1095.
86. Mashour N, Lin G, Frishman W. Herbal medicine for the treatment of cardiovascular disease. Arch Intern Med. 1998;158:2225-2234.
87. Monder C. Corticosteroids, kidneys, sweet roots and dirty drugs. Mol Cell Endocrinol. 1991;78: C95-C98.
88. Latif S, Conca T, Morris D. The effects of the licorice derivative, glycyrrhetinic acid, on hepatic 3 alpha- and 3 beta-hydroxysteroid dehydrogenases and 5 alpha- and 5 beta-reductase pathways of metabolism of aldosterone in male rats. Steroids. 1990;55:52-58.
89. Walker B, Edwards C. Licorice-induced hypertension and syndromes of apparent mineralocorticoid excess. Endocrinol Metab Clin North Am. 1994;23:359-377.
90. Sigurjonsdotir H, Ragnarsson J, Franzson L, Sigurdsson G. Is blood pressure commonly raised by moderate consumption of liquorice? J Hum Hypertens. 1995;9:345-348.
91. Sporanox (Itraconazole) [package insert]. Titusville, NJ: Jansen Pharmaceuticals; 2001.
92. Ahmad S, Leissa B. Congestive heart failure associated with itraconazole. Lancet. 2001;357: 1766-1767.